Nektar TherapeuticsNKTRNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +22.15% | -51.66% | -52.42% | -51.13% | -25.25% |
| Gross Profit Growth | +27.68% | -20.18% | -18.72% | -41.11% | +2.87% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | -208.08% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -233.05% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -596.89% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -442.31% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -449.02% |
| Weighted Average Shares Growth | +9.79% | +8.31% | +1.19% | +0.98% | +45.16% |
| Weighted Average Shares Diluted Growth | +11.81% | +8.31% | +1.19% | +0.98% | +42.54% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -28.55% | -68.45% | -53.40% | -39.28% | +10.57% |
| Inventory Growth | -100.00% | -100.00% | -100.00% | +0.00% | +0.00% |
| Asset Growth | -23.66% | -35.29% | -39.55% | -2.15% | -7.72% |
| Book Value per Share Growth | -57.76% | -89.99% | +0.00% | +72.36% | +1.89% |
| Debt Growth | -12.92% | -12.05% | -56.21% | -15.10% | +45.19% |
| R&D Expense Growth | -4.00% | +11.21% | +0.55% | -22.21% | +3.36% |
| SG&A Expenses Growth | -1.07% | +20.83% | -16.76% | -16.26% | -33.58% |